Illumina News and Activities

Illumina is one of the...

• Fortune 500 (#686);
• Russell 3000;
• TOB Iconic 10,000.

Illumina is a company listed under the stock ticker ILMN (US).

Illumina has 3 subsidiaries including Grail, Illumina Ventures and PacBio.

They are in:

• Biotechnology50%
• Medical Equipment25%
• Other25%

Acquisition, funding and merger involving Illumina.

• Illumina has acquired SomaLogic (posted on January 30 2026).
• Illumina has announced the acquisition of SomaLogic  (posted on June 23 2025).

View the org chart displaying its 95 main executives

Most searched biographies at Illumina

• Jacob Thaysen, Chief Executive Officer and Director
• Phil Schiller, Director
• David King, Director

Popular executive movements at Illumina

• David King has joined the company as Director  (posted on April 2 2026).
• Gary Guthart, Director, is retiring  (posted on April 2 2026).
• Robert Epstein, Director, is retiring  (posted on April 2 2026).

Click here to view some more movements at Illumina

Create your alert
to follow the executive moves at Illumina.

Illumina has 1,235 competitors including Thermo Fisher Scientific (United States (USA)), Medtronic (Ireland) and Philips (Netherlands).

Popular M&A news in Medical Equipment

• Niowave has just announced a $70 Million fundraising (posted on June 2 2026).
• The new name of Edap Tms is FocalTherics. (posted on June 1 2026).
• FocalTherics is now listed under ticker FOCL. (posted on May 31 2026).

Popular contacts in Medical Equipment

• Kweli Thompson - Executive Vice President and President, Neuroscience Portfolio at Medtronic
• Ivan Tornos - Chairman, President and Chief Executive Officer at Zimmer Biomet
• Marc Casper - Chairman of the Board, President and Chief Executive Officer at Thermo Fisher Scientific

Learn more about the Medical Equipment industry

Press releases by Illumina

• Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
• Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
• David P. King elected to Illumina's Board of Directors
• Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact
• Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
• DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows
• Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease
• Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026
• Illumina Announces Changes to Board of Directors
• Illumina advances preventive genomics through strategic consortium with Veritas Genetics
• View more press releases Close

Social media about Illumina

• Illumina on Wikipedia, Google News & Yahoo Finance
• Illumina on LinkedIn, X (Twitter) & YouTube